Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Strength in Numbers: EU Cross-Country Drug Pricing Coalitions Join Forces

Concerns Emerge Over Insufficient Data To Support Decision-Making

Executive Summary

Two groups of smaller European countries have agreed to collaborate on tackling challenges relating to accessing expensive new medicines.

You may also be interested in...

Nordic Countries To Agree Closer Collaboration On Joint Price Negotiation And Procurement

Five Nordic countries are agreeing a common strategy for closer collaboration on access to hospital drugs.

European Countries Issue Alzheimer’s Biomarker Warning

Biogen/Eisai’s Alzheimer’s drug aducanumab could face difficulties with health technology appraisal institutes should it win approval in the EU.

European Countries Should Join Forces To Lower Prices of Zolgensma & Kaftrio

The Dutch HTA institute is calling for hefty discounts of 50% and 75% for Novartis’s gene therapy and Vertex’s cystic fibrosis product.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts